Guided Therapeutics Overview
Get informed when a big investor buys or sells
+ Follow64.64%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Guided Therapeutics (GTHP) currently reports a ROE of 64.64%. That is above the sector sector average of 11.64%. Use the charts on this page to explore Guided Therapeutics's ROE history and peer comparisons.
Guided Therapeutics's ROE of 64.64% is higher than the its sector sector average of 11.64%. That is roughly 455.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Guided Therapeutics's current 64.64% should be judged against industry norms (sector average: 11.64%) and against GTHP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 64.64%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.64%. From there, open related valuation or income-statement pages for Guided Therapeutics, and consider following GTHP for alerts when major investors trade the stock.
